Xuriden® is a medicine approved for treating patients who have been diagnosed with hereditary orotic aciduria

Safety Information

• Contraindications – None

• Warning and Precautions – None

• Adverse reactions – No adverse reactions were reported with XURIDEN in patients with HOA

• Pregnancy (Section 8.1) – There are no available data on XURIDEN use in pregnant women to inform drug-associated risk

• Lactation (Section 8.3) – There are no data on the presence of XURIDEN in human milk, the effect on the breast-fed infant or the effect on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for XURIDEN and any potential adverse effects on the breastfed infant from XURIDEN or from the underlying maternal condition.

• Pediatric (Section 8.4) – The safety and effectiveness of XURIDEN have been established in pediatric patients. 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information.

This information is for U.S. residents only.  The information on this Web site should not take the place of talking with your doctor or health care professional.  
Xuriden® , Wellstat Therapeutics®, Wellstat®, and the “W” design are trademarks of Wellstat Therapeutics Corporation.

© Wellstat Therapeutics Corporation 2015, 2018